








Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer

AACR Annual Meeting Chicago IL
April 25-30, 2025
Poster section 51, Poster board # 4
Presentation LB422

Sofia Gkountela¹, William Tahaney², Vasiliki Vafeiadou¹, Christelle Bianda¹, Liam Cheeseman¹, Ambika Singh¹, Anna Diesslin¹, Martin Schillo¹, Sophia Nguyen², Luca Moccia¹, Christopher King², Yimao Liu², Chao Quan², Bradley DeMarco², Laura Schwander¹, Vaik Strande¹, Jessica Alers², Rajiv Narayan², Dave Peck², Sarah Pessa², Samuel Gilberto¹, John Castle¹, Filip Janku², Sharon Townson², Markus Warmuth², Magnus Walter¹, Beatrice Ranieri¹, Ralph Tiedt¹, Nina Ilic-Widlund²

¹Monte Rosa Therapeutics AG, WKL-136, Klybeckstrasse 191, 0457 Basel, Switzerland; ²Monte Rosa Therapeutics Inc., 321 Harrison Ave, Boston, MA 02118, United States



Conclusions

- The CDK2-directed molecular glue degrader MRT-51443 exhibits potency, selectivity, and favorable drug-like properties – without engaging the catalytic site or a G-loop
- Degradation of CDK2 inhibits CDK2-dependent cancer cell proliferation while displaying superior selectivity compared to clinical CDK2 inhibitors
- CDK2 degradation delays resistance to CDK4/6 inhibition *in vitro* and exhibits strong anti-tumor activity in combination with CDK4/6 inhibitors *in vivo*
- CDK2 degradation in combination with CDK4/6 inhibition and hormone therapy achieves superior efficacy compared to standard of care anti-CDK4/6 and anti-estrogen

Want to see what else molecular glues can do?